Bernstein raises Guardant Health stock price target on UnitedHealth coverage

Bernstein lifted its Guardant Health (GH) price target to $200 from $175 and kept an Outperform rating after UnitedHealth announced coverage for Shield (blood-based colorectal cancer screening) for adults 45+. The firm estimates Shield revenue nearly doubles in 2030 from $770M to ~$1.5B, and 2040 revenue rises from ~$3.3B to ~$4.1B, with incremental exposure to ~10M reimbursed customers. The stock has surged 19.5% over the past week and is trading near its 52-week high, while options activity increased alongside additional positive coverage changes and recent FDA approval for Guardant360 CDx.

Analysis

This is less about one reimbursement win and more about a validation event that can pull Shield from “future optionality” into a measurable utilization curve. The first-order upside is not just more covered lives; it is lower adoption friction for PCPs, employer plans, and health systems that were waiting for a large payer to break the logjam. That said, the real competitive pressure likely falls on stool-based screening and GI procedure volumes, not on UNH, which can absorb the claims cost unless utilization spikes far beyond underwriting assumptions.

The market is probably underestimating the lag between coverage and revenue. Screening products usually need multiple quarters of physician habit formation, patient acceptance, and claims adjudication before the curve steepens, so the next 1-3 months matter more for follow-on payer announcements than for near-term earnings beats. If no other major commercial payors follow by the next print, today’s rerating can unwind quickly because the valuation now discounts a very smooth adoption path.

Contrarian view: consensus is treating reimbursed lives as if they convert linearly into tests, but behavior change is the bottleneck. With the stock already pricing a lot of the long-dated opportunity, the bigger risk is not a failed thesis but an over-early thesis — the market may have moved ahead of actual volume data. The clearest falsifier is weak test count growth or lack of payer cascade over the next 1-2 quarters; the clearest upside trigger is confirmation from another national payer plus visible acceleration in reimbursed orders.

Key Decisions for Investors

• GH: do not chase the common after the recent rerate; wait for a 5-10% pullback or the next earnings print, then express upside via a 6-12 month call spread (e.g. 160/220) rather than outright equity. Risk/reward improves if payer follow-through arrives, and downside is defined to premium.
• GH vs EXAS: if a second large commercial payer follows within 1-2 quarters, consider a relative-value long GH / short EXAS pair to express blood-test share gains against the incumbent noninvasive screening leader. Falsify if volumes on GH fail to inflect faster than expected.
• UNH: no direct short; the reimbursement burden looks immaterial versus the long-cycle economics. Use as a watch item only — if UNH or peers explicitly push back on coverage economics, that would be the first sign the adoption story is overdone.